Who are Immediate-release Guaifenesin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): DEXTROMETHORPHAN HYDROBROMIDE, Mucinex, Mucinex® SE, Guaifenesin Syrup, Ivy Leaves Cough Liquid, Mucinex®.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/immediate-release-guaifenesin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Immediate-release Guaifenesin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Immediate-release Guaifenesin (Immediate-release Guaifenesin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Expectorant. Area: Respiratory.

phase 2 Expectorant Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

Immediate-release Guaifenesin (Immediate-release Guaifenesin) — Reckitt Benckiser LLC. Guaifenesin is an expectorant that works by increasing the volume and reducing the viscosity of respiratory tract secretions.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Immediate-release Guaifenesin TARGET	Immediate-release Guaifenesin	Reckitt Benckiser LLC	phase 2	Expectorant
DEXTROMETHORPHAN HYDROBROMIDE	DEXTROMETHORPHAN HYDROBROMIDE		marketed	Expectorant [EPC]		1984-01-01
Mucinex	guaifenesin	Generic (multiple manufacturers)	marketed	Expectorant [EPC]	Vagal gastric reflex → increased respiratory secretions	1952-01-01
Mucinex® SE	Mucinex® SE	Reckitt Benckiser Inc.	marketed	Expectorant
Guaifenesin Syrup	Guaifenesin Syrup	Liaoning University of Traditional Chinese Medicine	marketed	Expectorant
Ivy Leaves Cough Liquid	Ivy Leaves Cough Liquid	Engelhard Arzneimittel GmbH & Co.KG	marketed	Herbal expectorant
Mucinex®	Mucinex®	Reckitt Benckiser LLC	marketed	Expectorant

Recent regulatory actions (last 90 days)

2026-03-12 — DEXTROMETHORPHAN HYDROBROMIDE · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Expectorant class)

Reckitt Benckiser LLC · 2 drugs in this class
American Health Research · 1 drug in this class
EMS · 1 drug in this class
Guang'anmen Hospital of China Academy of Chinese Medical Sciences · 1 drug in this class
Liaoning University of Traditional Chinese Medicine · 1 drug in this class
Reckitt Benckiser Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Immediate-release Guaifenesin — Competitive Intelligence Brief. https://druglandscape.com/ci/immediate-release-guaifenesin. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing